Skip to main content

Table 4 Analysis of cost-effectiveness of each screening strategy

From: Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis

Cost-effectiveness Measures TST T-SPOT.TB QFT-GIT TST/T-SPOT.TB TST/QFT-GIT
Total costs of screening £199,589 £203,983 £202,921 £162,387 £157,048
Incremental cost of screening (compared to no screening) £142,442 £146,836 £145,774 £105,240 £99,901
Active TB cases prevented 2.98 3.70 3.47 2.83 2.65
Cost per active TB case prevented £67,034 £55,168 £58,536 £57,410 £59,265
Incremental cost per active case prevented (compared to no screening) £47,840 £39,712 £42,051 £37,206 £37,699
Savings per active TB case prevented (compared to TST) - £8,128 £5,790 £10,634 £10,141
  1. All costs are expressed in British pounds (£). Cost-effectiveness relates to outcomes and costs for entire cohort of 1,000 contacts over the 2 year examination period. (TST - Tuberculin Skin Test, QFT-GIT - Quantiferon-TB Gold-In-Tube)